- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02675257
Depression and Diabetes Control Trial (DDCT)
Study Overview
Status
Conditions
Intervention / Treatment
- Behavioral: Diabetes-related affective problems analysis
- Behavioral: Goal setting towards improvement of glycaemic control
- Behavioral: Diabetes-specific problem-solving therapy
- Behavioral: Interventions to increase diabetes treatment motivation
- Behavioral: Activation of personal and social resources
- Behavioral: Reduction of barriers to self-care/glycaemic control
- Behavioral: Cognitive restructuring of diabetes-related problems
- Behavioral: Goal definition regarding self-care/glycaemia/well-being
- Behavioral: Health care and specific topics (e. g. blood pressure)
- Behavioral: Healthy foods, cooking recommendations, recipes
- Behavioral: Sports, activities and exercise
- Behavioral: Foot care: exercises, care & control, injuries, neuropathy
- Behavioral: Diabetes complications
- Behavioral: Social aspects of living with diabetes
Detailed Description
Suboptimal glycaemic control is an established risk factor for the development of serious long-term complications of diabetes. Moreover, it is associated with elevated risks of significant hyperglycaemic acute events such as hyperosmolar hyperglycemic state or diabetic ketoacidosis. Hence, patients with diabetes and persistent suboptimal glycaemic control are at higher risk of having a rather poor prognosis.
Besides physiological and medical factors, psychological problems have been found to predict suboptimal glycaemic control. A number of studies found depressive symptoms to be independently associated with hyperglycaemia. Others focussed on diabetes-specific affective problems - the so called diabetes distress - and suggested this factor to be of great importance. Finally, some studies found that depressive symptoms and diabetes distress may interact, with the coocurrence of these factors being associated with the highest risk or suboptimal glycaemic control. The results correspond to other findings suggesting that both depressive symptoms and diabetes distress are often associated with reduced diabetes self-care, which can explain the associations of those factors with hyperglycaemia.
On the other hand, suboptimal glycaemic control could also be an explanation for affective problems - either mediated by physiological mechanisms or psychological ones, e.g. dissatisfaction or guilt. Hence, it is valid to assume that the link between depressive symptoms and/or diabetes distress may be bidirectional - although evidence to support this assumption is missing.
Following this evidence and background, the investigators designed the a to analyse the relationships between suboptimal glycaemic control, depressive symptoms and diabetes distress in diabetes using a prospective study design. The study is a randomized trial in which a cognitive-behavioural group treatment is compared to a treatment-as-usual condition (standard diabetes education) regarding their efficacy in improving suboptimal glycaemic control. 212 diabetes patients with suboptimal glycaemic control (HbA1c value > 7.5%) and elevated depressive symptoms (Center for Epidemiologic Studies Depressions Scale score ≥ 16) and/or elevated diabetes distress (Problem Areas In Diabetes Scale score ≥ 40) will be randomly assigned to either the treatment group or treatment-as-usual. The primary outcome is the improvement of suboptimal glycaemic control (reduction of HbA1c) in the 12-month follow-up. As secondary outcomes positive baseline-to-follow up changes regarding depressive symptoms, diabetes distress, diabetes self-care behaviour, diabetes acceptance and quality of life are assessed.
A second study objective is to analyse cross-sectional and prospective associations of suboptimal glycaemic control, depressive symptoms and diabetes distress with serum levels of the following inflammatory markers: hsCRP, IL-6, IL-18, IL-1Ra, MCP-1 and Adiponectin. Potential effects of the treatment groups on these markers will also be examined.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
BW
-
Bad Mergentheim, BW, Germany, 97980
- Diabetes Center Mergentheim
-
-
Baden-Württemberg
-
Bad Mergentheim, Baden-Württemberg, Germany, 97980
- Forschungsinstitut der Diabetes Akademie Mergentheim e. V.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age between 18 and 70
- Diabetes mellitus type 1 or type 2
- Diabetes duration ≥ 1 year
- Suboptimal glycaemic control (HbA1c > 7,5%)
- Elevated depressive symptoms (CES-D score ≥ 16) and/or elevated diabetes distress (PAID score ≥ 40)
- Sufficient language skills
- Written informed consent
Exclusion Criteria:
- Severe major depressive disorder according to ICD-10
- Current psychiatric and/or psychotherapeutic treatment
- Current antidepressive medical treatment
- Suicidal ideation
- Acute mental disorder of the following type: schizophrenia or other psychotic disorder, bipolar disorder, severe eating disorder (anorexia nervosa, bulimia nervosa), substance use disorder
- History of personality disorder
- Severe somatic illnesses: dialysis-dependent nephropathy, acute cancer, severe heart disease (NYHA III - IV), severe neurologic illness (e. g. MS, dementia), severe autoimmune disease
- Terminal illness
- Bedriddenness
- Guardianship
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cognitive-behavioural group treatment
Five group sessions of diabetes-Specific cognitive-behavioural group treatment for diabetes patients with depressive symptoms and/or diabetes distress and suboptimal glycaemic control. Interventions:
|
Analysis of diabetes-related affective problems with regard to suboptimal glycaemic control
Discussing and setting goals regarding improvements of suboptimal glycaemic control, depressive symptoms and diabetes distress
Diabetes-specific problem-solving therapy with main focus on suboptimal glycaemic control, depressive symptoms and diabetes distress
Interventions to increase diabetes treatment motivation in order to achieve improvements of glycaemic control as well as recovery from affective problems
Activation of personal and social resources with a view to diabetes control and affective problems
Definition and reduction of barriers to adequate diabetes self-care behaviour as well as good glycaemic control
Cognitive restructuring of diabetes-related problems such as suboptimal glycaemic control and diabetes-related affective problems
Goal definition and agreement regarding diabetes self-care behaviour, optimal glycaemic control and activities supporting well-being and recovery from affective symptoms
|
Active Comparator: Treatment-as-usual
Standard diabetes education. Interventions:
|
Education on health care and specific topics (e. g. blood pressure)
Education on healthy and unhealthy foods, cooking and recipes
Education on sports, activities and exercise
Education on foot care: exercises, care and control, injuries, and diabetic neuropathy
Education on diabetes complications
Education on social aspects of living with diabetes
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Improvement of glycaemic control as measured by the HbA1c
Time Frame: 12 months
|
Mean difference between HbA1c values at baseline and at 12 month follow
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Improvement of glycaemic control as measured by participants' blood glucose meter or glucose monitoring devices (data are extracted from tools using the diasend application)
Time Frame: 12 months
|
Mean difference between average glucose test scores during an 8-week period before baseline and those during an 8-week period before 12 month follow
|
12 months
|
Improvement of depressive symptoms as measured with the Center for Epidemiologic Studies Depression Scale (CES-D)
Time Frame: 12 months
|
Mean difference between CES-D scores at baseline and at 12 month follow up
|
12 months
|
Improvement of depressive symptoms as measured with the Patient Health Questionnaire Module for Depression (PHQ-9)
Time Frame: 12 months
|
Mean difference between PHQ-9 scores at baseline and at 12 month follow up
|
12 months
|
IImprovement of diabetes distress as measured with the Problem Areas in Diabetes Scale (PAID)
Time Frame: 12 months
|
Mean difference between PAID scores at baseline and at 12 month follow
|
12 months
|
IImprovement of diabetes distress as measured with the Diabetes Distress Scale (DDS)
Time Frame: 12 months
|
Mean difference between DDS scores at baseline and at 12 month follow
|
12 months
|
Improvement of self-care behaviour as measured with the Summary of Diabetes Self-Care Activities Measure (SDSCA)
Time Frame: 12 months
|
Mean difference between SDSCA scores at baseline and at 12 month follow
|
12 months
|
Improvement of self-care behaviour as measured with the Diabetes Self-Management Questionnaire (DSMQ)
Time Frame: 12 months
|
Mean difference between DSMQ scores at baseline and at 12 month follow
|
12 months
|
Improvement of diabetes acceptance as measured with the Diabetes Acceptance Scale (DAS)
Time Frame: 12 months
|
Mean difference between DAS scores at baseline and at 12 month follow
|
12 months
|
Improvement of quality of life as measured with the EuroQol Five-Dimensions Questionnaire (EQ-5D)
Time Frame: 12 months
|
Mean difference between EQ-5D scores at baseline and at 12 month follow
|
12 months
|
Improvement of quality of life as measured with the Short Form-36 Health Survey (SF-36)
Time Frame: 12 months
|
Mean difference between SF-36 scores at baseline and at 12 month follow
|
12 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Inflammatory Marker: hsCRP
Time Frame: 12 months
|
Mean difference between hsCRP scores at baseline and at 12 month follow
|
12 months
|
Inflammatory Marker: IL-6
Time Frame: 12 months
|
Mean difference between IL-6 scores at baseline and at 12 month follow
|
12 months
|
Inflammatory Marker: IL-18
Time Frame: 12 months
|
Mean difference between IL-18 scores at baseline and at 12 month follow
|
12 months
|
Inflammatory Marker: IL-1Ra
Time Frame: 12 months
|
Mean difference between IL-1Ra scores at baseline and at 12 month follow
|
12 months
|
Inflammatory Marker: MCP-1
Time Frame: 12 months
|
Mean difference between MCP-1 scores at baseline and at 12 month follow
|
12 months
|
Inflammatory Marker: Adiponectin
Time Frame: 12 months
|
Mean difference between Adiponectin scores at baseline and at 12 month follow
|
12 months
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Thomas Haak, Prof., MD, Diabetes Center Mergentheim
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- FKZ 82DZD01101
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depression
-
ProgenaBiomeRecruitingDepression | Depression, Postpartum | Depression, Anxiety | Depression Moderate | Depression Severe | Clinical Depression | Depression in Remission | Depression, Endogenous | Depression ChronicUnited States
-
Washington University School of MedicineCompletedTreatment Resistant Depression | Late Life Depression | Geriatric Depression | Refractory Depression | Therapy-Resistant DepressionUnited States, Canada
-
University of California, San FranciscoRecruitingDepression Moderate | Depression Mild | Depression, TeenUnited States
-
University GhentUniversiteit Antwerpen; Janssen-Cilag Ltd.RecruitingDepression Moderate | Depression Severe | Depression MildBelgium
-
Baylor College of MedicineUniversity of TexasRecruitingDepression | Depression Moderate | Depression Severe | Suicide and Self-harm | Depression in Adolescence | Depression MildUnited States
-
University of Cape TownNational Institute of Mental Health (NIMH)CompletedPostpartum Depression | Clinical Depression | Moderate DepressionSouth Africa
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; National Institute of Mental...CompletedMajor Depressive Disorder | Treatment Resistant Depression | Treatment-Refractory Depression | Late Life Depression | Geriatric DepressionUnited States, Canada
-
Gerbera Therapeutics, Inc.Not yet recruitingPostpartum Depression | Depression, Postpartum | Postnatal Depression | Post-partum Depression | Post-Natal DepressionUnited States
-
Lawson Health Research InstituteTerminated
-
Northern Illinois UniversityUniversity Autonoma de Santo DomingoTerminatedDepression Moderate | Depression MildUnited States, Dominican Republic
Clinical Trials on Diabetes-related affective problems analysis
-
University Hospital, MontpellierCompleted
-
Fundació Institut de Recerca de l'Hospital de la...UnknownPharmaceutical Care | Drug Related ProblemsSpain
-
Hacettepe UniversityCompletedCardiac Surgery | Drug Related Problems | Clinical Pharmacy | Risk AssesmentTurkey
-
Beijing Institute of Heart, Lung and Blood Vessel...UnknownCardiovascular Diseases | Sleep | Cardiovascular Risk Factor | Aging Problems | Smell DisorderChina
-
Federal University of Rio Grande do SulCompletedDiabetes Mellitus, Type 2 | Diabetes Mellitus, Type 1 | COVIDBrazil
-
University of CologneNot yet recruiting
-
National University of SingaporeActive, not recruitingAnxiety | Educational Problems | Marriage Age | Childbearing, Delayed | Age Related Female InfertilitySingapore
-
Universidad Miguel Hernandez de ElcheEuropean Research Council; Pontificia Universidad Católica del Ecuador; Centro...UnknownDiabetes Mellitus, Type 2Ecuador
-
University Hospitals Cleveland Medical CenterNational Institute of Mental Health (NIMH)CompletedType 1 Diabetes MellitusUnited States
-
NorthShore University HealthSystemCompleted